Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | March 31, 2021 | April 02, 2021 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 13, 2024 | May 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 26,648.481 |
Reported balance
After 2021-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-31 · Grant · Acquired 554.412 · Balance 26,648.481 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 13, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,802 |
Ending reported balance
After 2024-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-13 · Grant · Acquired 559 · Balance 32,408 F1: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2024-05-13 · Grant · Acquired 394 · Balance 32,802 F2: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $228.41 · Expires 2034-05-13 | Direct | 1,311 |
Reported balance
After 2024-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-13 · Grant · Acquired 1,311 · Balance 1,311 F3: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders.
F3: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 03, 2009 · Filed November 04, 2009
Section 16 reporting ended · disclosed 2009-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 1
1 source rowRow 1 · 2009-11-03 · Disposition to issuer · Disposed 104,616 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. |
| Common SharesSEC Table I · non-derivative | IndirectBy 401(k) | 0 |
Reported balance
After 2009-11-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2009-11-03 · Disposition to issuer · Disposed 6,099.41 · Balance 0 F2: In connection with the Merger, each share held in the Issuer's stock fund of the Issuer's 401(k) plan was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Both the shares and cash will remain in the plan until such time as the reporting person elects a distribution therefrom. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2013-05-18 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2009-11-03 · Disposition to issuer · Disposed 240,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.87 · Expires 2013-11-16 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2009-11-03 · Disposition to issuer · Disposed 350,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2014-02-22 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-11-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.57 · Expires 2014-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-11-03 · Disposition to issuer · Disposed 345,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.70 · Expires 2015-04-24 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2009-11-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2015-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2009-11-03 · Disposition to issuer · Disposed 260,000 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2016-04-30 | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2009-11-03 · Disposition to issuer · Disposed 264,600 · Balance 0 F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter. |
| Phantom Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2009-11-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2009-11-03 · Disposition to issuer · Disposed 65,587.15 · Balance 0 F5: Each unit of phantom stock is the economic equivalent of one share of common stock. F6: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Merck & Co., Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash.
F2: In connection with the Merger, each share held in the Issuer's stock fund of the Issuer's 401(k) plan was converted into 0.5767 shares of Merck & Co., Inc. common stock and $10.50 in cash. Both the shares and cash will remain in the plan until such time as the reporting person elects a distribution therefrom.
F3: The options vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or the reporting person's termination of employment thereafter.
F4: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F5: Each unit of phantom stock is the economic equivalent of one share of common stock.
F6: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 15, 2024 21:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,311 | $228.41 Strike: $228.41 | $299,445.51 |
DisclosureSEC source: 0001127602-24-015525 · form4.xml · derivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311 Underlying: Common Stock · 1,311 shares Expires 2034-05-13 F3 · shares: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 394 | $228.41 | $89,993.54 |
DisclosureSEC source: 0001127602-24-015525 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,802 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 559 | $228.41 | $127,681.19 |
DisclosureSEC source: 0001127602-24-015525 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,408 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,669 | $192.36 Strike: $192.36 | $321,048.84 |
DisclosureSEC source: 0001127602-23-015842 · form4.xml · derivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires 2033-05-15 F3 · shares: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 468 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015842 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,849 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015842 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,381 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,582 | $222.31 Strike: $222.31 | $351,694.42 |
DisclosureSEC source: 0001127602-22-014401 · form4.xml · derivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582 Underlying: Common Stock · 1,582 shares Expires 2032-05-11 F3 · shares: The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 405 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014401 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,717 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 10, 2022. The restricted stock units vest upon the earlier of 5/11/2023, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014401 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,312 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $342.55 | $0.00 |
DisclosureSEC source: 0001127602-21-016100 · form4.xml · derivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-07 F3 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016100 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,737 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016100 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,489 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 17:22 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 554.412 | $63.13 | $35,000.03 |
DisclosureSEC source: 0000014272-21-000121 · wf-form4_161738408933001.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,648.481 Underlying: Common Stock, $0.10 par value · 554.412 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,054.171 | $62.21 | $189,999.98 |
DisclosureSEC source: 0000014272-21-000052 · wf-form4_161239788421605.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,094.069 Underlying: Common Stock, $0.10 par value · 3,054.171 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:10 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 564.243 | $62.03 | $34,999.99 |
DisclosureSEC source: 0000014272-21-000017 · wf-form4_160989538863498.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,859.843 Underlying: Common Stock, $0.10 par value · 564.243 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 580.527 | $60.29 | $34,999.97 |
DisclosureSEC source: 0000014272-20-000266 · wf-form4_160167065837612.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,128.215 Underlying: Common Stock, $0.10 par value · 580.527 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:00 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 595.238 | $58.80 | $34,999.99 |
DisclosureSEC source: 0000014272-20-000214 · wf-form4_159372355114736.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,384.859 Underlying: Common Stock, $0.10 par value · 595.238 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 20, 2020 Filed May 21, 2020 15:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,530 | $0.00 Strike: $52.29 | $0.00 |
DisclosureSEC source: 0001127602-20-017466 · form4.xml · derivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,530 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 21, 2020 15:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,530 | $174.58 | $616,262.81 |
DisclosureSEC source: 0001127602-20-017466 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,134 F1 · price: This transaction was executed in multiple trades at prices ranging from $174.50 to $174.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2020 Filed May 21, 2020 15:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,530 | $52.29 | $184,583.70 |
DisclosureSEC source: 0001127602-20-017466 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-20-016261 · form4.xml · derivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 F3 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 518 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016261 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,134 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 6, 2020. The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016261 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,616 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:50 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 627.915 | $55.74 | $34,999.98 |
DisclosureSEC source: 0000014272-20-000142 · wf-form4_158586062026633.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,635.524 Underlying: Common Stock, $0.10 par value · 627.915 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,140 | $0.00 Strike: $70.29 | $0.00 |
DisclosureSEC source: 0001127602-20-005477 · form4.xml · derivative · entry 5 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,140 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,030 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001127602-20-005477 · form4.xml · derivative · entry 4 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,030 shares Expires 2020-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7,170 | $170.41 | $1,221,818.91 |
DisclosureSEC source: 0001127602-20-005477 · form4.xml · nonDerivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,875 F1 · price: This transaction was executed in multiple trades at prices ranging from $169.925 to $170.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,140 | $70.29 | $220,710.60 |
DisclosureSEC source: 0001127602-20-005477 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,030 | $43.39 | $174,861.70 |
DisclosureSEC source: 0001127602-20-005477 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 23:02 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,018.268 | $62.95 | $189,999.97 |
DisclosureSEC source: 0000014272-20-000059 · wf-form4_158085733724072.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,007.609 Underlying: Common Stock, $0.10 par value · 3,018.268 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 23:48 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 516.046 | $64.19 | $33,124.99 |
DisclosureSEC source: 0000014272-20-000015 · wf-form4_157809528682368.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,869.941 Underlying: Common Stock, $0.10 par value · 516.046 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 653.224 | $50.71 | $33,124.99 |
DisclosureSEC source: 0000014272-19-000175 · wf-form4_157004946408417.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,237.429 Underlying: Common Stock, $0.10 par value · 653.224 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 21:06 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | PurchaseCommon Stock, $0.10 par value | 11,000 | $44.72 | $491,920.00 |
DisclosureSEC source: 0000014272-19-000162 · wf-form4_156469358075770.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,397 F1 · shares: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $44.71 to $44.73, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:12 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 730.43 | $45.35 | $33,125.00 |
DisclosureSEC source: 0000014272-19-000139 · wf-form4_156210195577406.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,444.114 Underlying: Common Stock, $0.10 par value · 730.43 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019562 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,875 F2 · kind: The grant was made in lieu of director service fees for the term commencing May 21, 2019. The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019562 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,218 F1 · kind: Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 694.299 | $47.71 | $33,125.01 |
DisclosureSEC source: 0000014272-19-000093 · wf-form4_155423750523262.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,585.304 Underlying: Common Stock, $0.10 par value · 694.299 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,708.158 | $49.89 | $185,000.00 |
DisclosureSEC source: 0000014272-19-000031 · wf-form4_154940317062203.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,891.005 Underlying: Common Stock, $0.10 par value · 3,708.158 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:29 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 637.264 | $51.98 | $33,124.98 |
DisclosureSEC source: 0000014272-19-000011 · wf-form4_154655092334381.xml · derivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,968.765 Underlying: Common Stock, $0.10 par value · 637.264 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $135.15 | $13,515.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 10 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,336 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $135.06 | $13,506.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 9 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,436 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $135.04 | $13,504.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 8 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,536 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $135.03 | $13,503.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 7 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,636 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $135.01 | $13,501.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 6 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,736 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.50 | $13,450.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 5 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,836 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $134.49 | $26,898.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 4 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,936 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.47 | $13,446.50 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 3 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,136 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.37 | $13,436.50 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 2 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,236 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $134.19 | $13,419.00 |
DisclosureSEC source: 0001127602-18-035269 · form4.xml · nonDerivative · entry 1 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,336 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 13:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,540 | $0.00 Strike: $33.93 | $0.00 |
DisclosureSEC source: 0001127602-18-035267 · form4.xml · derivative · entry 30 BERTOLINI ROBERT J · CIK 0001270263 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,540 shares Expires 2019-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.